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Neuropeptide S:
A Novel Activating Anxiolytic?
Many different neuropharmacological agents modu-
late arousal and anxiety, yet to date, few endogenous
substances have produced arousal with an anxiolytic
effect. In this issue of Neuron, Xu et al. describe the
localization and characterization of a novel neuropep-
tide, neuropeptide S (and its cognate receptor), that
is unique in its arousing and anxiolytic-like properties.
The article by Xu and colleagues (Xu et al., 2004 [this
issue of Neuron]) provides evidence of a potential novel
brain modulator of arousal and anxiety using animal
models. The authors describe the anatomical localiza-
tion and behavioral characterization of a novel neuro-
peptide, neuropeptide S (NPS), and its cognate recep-
Figure 1. Possible Neuropeptide S Circuit in Arousaltor. NPS is localized to brain pontine regions, such as
Corticotropin-releasing factor (CRF) neurons in Barrington’s nu-the peri-locus coeruleus and Barrington’s nucleus. NPS
cleus, the central nucleus of the amygdala (CeA), and the bed nu-is also localized to the amygdala, an area important for
cleus of the stria terminalis (BNST) project to the pons, as well asanxiety function. The NPS receptor is seen in highest
hypocretin/orexinergic neurons (Hcrt) from the hypothalamus. NPS
abundance in amygdala, anterior olfactory nucleus, en- neurons in the peri-locus coeruleus, as well as nearby noradrenergic
dopiriform nuclei, paraventricular thalamic nucleus, su- (NE) neurons in the locus coeruleus (LC), project to the forebrain,
possibly as part of an arousal projection (Foote et al., 1980; vanbiculum, and several cortical regions. Intracerebroven-
Bockstaele et al., 1998; Sutcliffe and de Lecea, 2002).tricular administration of NPS at doses of 0.1 nmol and
1 nmol caused increased motor activity and also pro-
moted wakefulness. At similar doses, NPS also was
found to have anxiolytic-like properties, using open field, themselves to be calmer and more relaxed. The compar-
ison of NPS to nicotine leads to the question as tolight-dark box, elevated plus maze, and marble burying
paradigms. NPS and its receptor are hypothesized to whether an interaction between NPS and nicotine ulti-
mately may be found. NPS and future analogs derivedbe involved in arousal and anxiety, based on their brain
localization and behavioral results. To our knowledge, from NPS could be excellent tools for further character-
izing arousal and anxiety function in the brain and possi-this manuscript provides the first description of the lo-
calization and behavioral effects of NPS. Thus, NPS may bly teasing apart separate systems that may underlie
these two behaviors. Interaction with the NPS systembe an important novel neuropeptide mediating arousal
and anxiety behaviors. could also potentially provide important therapeutic
uses for sleep, anxiety disorders, and depression.There are several important experimental and concep-
tual strengths to this work that make it particularly note- Second, the experimental strength of the Xu et al.
study lies in the careful attention to the use of validatedworthy. First, from a conceptual framework, NPS ap-
pears to produce behavioral activation and induce measures of anxiety to test the hypothesis at hand. Here,
NPS produced increases in exploratory behavior in ani-wakefulness, but at the same time produces an anxio-
lytic-like effect. To some extent, this is a paradox—most mal models of anxiety where anxiety is manifest as an
inhibition in behavior (such as the elevated plus maze)drugs that are arousing and activating ultimately pro-
duce anxiety-like effects, not anxiolytic-like effects (for but produced inhibition of behavior in tests where anxi-
ety-like effects are reflected in an active response (mar-example, cocaine, amphetamines, -aminobutyric acid
antagonists, and corticotropin-releasing factor [Sutton ble burying). Such a dual approach to validated animal
models lends assurance that nonspecific (locomotor)et al., 1982; Koob and Heinrichs, 1999; Koob et al.,
2004]). An exception to this rule is nicotine, a drug which activation or depression in behavior are not influencing
the measures used to hypothesize anxiolytic-like effectsalso increases arousal and wakefulness and produces
anxiolytic-like, antistress effects. Long documented, and lend more credence to an antianxiety action of NPS.
Further statistical analysis within a given animal modelthis paradox has been held as an example of how
arousal and stress do not always follow a monophasic of anxiety also confirmed a loading on the anxiolytic
measure. Obviously, small molecule compounds will becontinuum. Nesbitt (1973) allowed smokers to smoke
during a stressful experience (sessions where they re- required to test this hypothesis in humans and to deter-
mine if there is any functional role for NPS in the arousal/ceived painful shocks), and these smokers showed more
arousal (increase in pulse rate) but reported less emotion anxiety domain.
The anatomical localization of NPS also provides(more pain endurance, more shocks taken) than smok-
ers that were not allowed to smoke but that simulated some intriguing links to long-hypothesized pontine roles
in sleep, waking, and arousal. NPS is not localized withinsmoking. These early results were interpreted to support
the Nesbitt paradox that is reported by smokers—that the locus coeruleus (LC). Neuropeptide S-expressing
neurons do not produce norepinephrine, and locus coer-their physiological arousal is increased but they report
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uleus norepinephrine neurons do not contain NPS re- issue of Neuron, Kanai et al. use affinity chromatogra-
ceptor mRNA. Indeed, there appears to be a cluster of phy and mass spectrometry to identify a large number
NPS-expressing neurons in the pons that do not pro- of new factors that associate with kinesin, a molecular
duce either norepinephrine or corticotropin-releasing motor, and employ siRNA technology to demonstrate
factor but that are located in-between the locus coeru- their importance for RNA transport in neurons.
leus (norepinephrine) and Barrington’s nucleus (cortico-
tropin-releasing factor). NPS cells located in the pons, Often times, cells concentrate certain proteins in partic-
where they are most abundant, could be involved in an ular regions so that the metabolic events that they cata-
arousal projection from the pons to rostral areas of the lyze occur only locally. How they accomplish this task
brain, including the cortex, amygdala, and thalamus, depends on the cell and the protein, but consider three
where its cognate receptor is localized (see Figure 1). general possibilities: make the protein everywhere but
Thus, the peri-locus coeruleus NPS neuronal system destroy it where it is not needed, distribute mRNA en-
could be a novel and important component of a cortical coding the protein everywhere but translate it only lo-
arousal system that has long been hypothesized to be cally, or transport the mRNA in a silent form to the place
part of the reticular activating system (Moruzzi and Ma- where it is to be translated. The transport of silent mRNA
goun, 1949). would seem to be especially complicated, as it would
In summary, the novel neuropeptide NPS has been require three sets of machinery: that needed for moving
localized in the brain in areas that are relevant for arousal the cargo, for keeping the RNA silent while it is being
and wakefulness and at the same time presents with a moved, and for activating the mRNA once it arrives at
profile of an anxiolytic in animal models of anxiety. This its destination. In neurons, a variety of mRNAs are trans-
contrasts with its pontine neighbors norepinephrine (which ported into dendrites, quite possibly in a quiescent state;
increases arousal but can have stress-like effects), hypo- the products of these mRNAs, which are thought to be
cretin/orexin A (which increases arousal and has little synthesized at or near activated synapses, may then
stress-like effects but may have aversive effects), and modify synaptic plasticity (Martin et al., 2000). These
corticotropin-releasing factor (which increases arousal working hypotheses are based mostly on reporter RNA
and has stress-like and aversive effects). Such a sym- assays and/or the application of protein synthesis inhibi-
phony of arousal-activating neuropeptides located in tors to brain slices or neurons in culture, which have
the pons may provide insight into the regulation of been very useful in identifying cis elements that direct
arousal and wakefulness, and NPS appears to be a new mRNAs to dendrites as well as for demonstrating the
key player. importance of some newly synthesized protein(s) in
plasticity. However, without loss-of-function type exper-
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Neurons contain several isoforms of kinesin (KIFs),RNA Transport (Partly) Revealed! the molecular motor that directs cargos to the plus ends
of microtubules. Because the microtubules are arrayed
with their plus ends extending into dendrites, the kines-
ins have long been thought to direct RNA-containingSpecific mRNAs are transported to dendrites where
their translation may modify synaptic plasticity. In this cargoes, which appear granular or particulate in nature,
